4 Jul 2014
The SCI Fine Chemicals Group is hosting two one-day medicinal chemistry events on consecutive days in Belgrave Square, London on 13-14 October 2014. Discounted registration is available for attendance on both days.
Amongst the key challenges faced by a medicinal chemist is the increasing demand to produce better quality drug candidates with a reduced likelihood of attrition in the clinic. It is estimated that just a 5-10% reduction in the attrition rate, which is largely linked with toxicology, could double the output of marketed drugs. The SCI Fine Chemicals Group’s forthcoming Designing Safer Medicines: What Works and What Doesn't seminar is the second such meeting in this series, at which some practical insights into the recent improvements in this area will be put forward. Topics to be addressed include cross-company data sharing, multiparametric models for predicting drug safety and case studies in toxicological issues in drug discovery.
On the day after this event, the SCI Fine Chemicals Group is also hosting a day seminar entitled Highlights in Medicinal Chemistry, which will showcase vignettes of modern medicinal chemistry excellence in a short presentation format. Confirmed talks cover a range of medicinal chemistry programmes from oncology to inflammation, from oral to inhaled, from kinases to PPIs but each with the objective to share a key message or learning applicable to the medicinal chemist.
The meetings have been put together by leaders in industry including representatives from Argenta, AstraZeneca, Evotec, MedChemica, Pfizer, and Vertex and are designed for both academic and industrial scientists engaged in all aspects of the drug discovery process. As well as a series of cutting edge scientific talks on both days, there will be ample opportunity for networking with speakers and delegates during refreshment breaks and wine receptions. Sponsorship and exhibition opportunities are available by contacting SCI’s Fine Chemicals Group.